Login to Your Account



Approach Can Still Deliver

Osiris' Stem-Cell 'Road Bump' Not a Signal for Slowing Down

By Randy Osborne


Monday, September 14, 2009
Osiris Therapeutics Inc.'s double-barreled Phase III blowup last week with Prochymal for graft-vs.-host disease sent shivers through the stem-cell therapy community, vindicating nay-sayers who'd been predicting failure of the leading product candidate.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription